临床肝胆病杂志2026，Vol.42Issue(2)：278-285,8.DOI:10.12449/JCH260205
丁型肝炎病毒治疗药物的研究进展
Research advances in antiviral drugs for the treatment of hepatitis D virus infection
刘阳 1祁永和 2周忠敏 2隋建华 2李文辉3
作者信息
- 1. 华辉安健(北京)生物科技有限公司,北京 102206||北京生命科学研究所,北京 102206
- 2. 华辉安健(北京)生物科技有限公司,北京 102206
- 3. 北京生命科学研究所,北京 102206||清华大学生物医学交叉研究院,北京 100084
- 折叠
摘要
Abstract
Co-infection of hepatitis D virus(HDV)and hepatitis B virus(HBV)is the most severe form of viral hepatitis and is associated with accelerated progression of liver disease and a significant increase in the risk of liver cirrhosis and hepatocellular carcinoma.Nucleo(s)tide analogues for HBV treatment are ineffective against HDV infection,necessitating the urgent need for developing specific and effective antiviral therapies for HDV.In recent years,significant advances have been made in the research and development of specific antiviral drugs against HDV,including entry inhibitors targeting viral entry(Bulevirtide)and monoclonal antibody drugs(Libevitug),which bring ground-breaking advances in the treatment of HDV infection.This article briefly reviews the latest research advances in therapeutic drugs for HDV,introduces the mechanism of action and clinical research data of new drugs recently approved for the treatment of HDV,and discusses the challenges that need to be solved in the field of HDV treatment,in order to provide a reference for understanding the current status of hepatitis D treatment.关键词
δ肝炎病毒/抗病毒药/布来韦肽/立贝韦塔单抗Key words
Hepatitis Delta Virus/Antiviral Agents/Bulevirtide/Libevitug引用本文复制引用
刘阳,祁永和,周忠敏,隋建华,李文辉..丁型肝炎病毒治疗药物的研究进展[J].临床肝胆病杂志,2026,42(2):278-285,8.
